华东医药股份有限公司

Group 1 - The core viewpoint of the article is that the audit committee of East China Pharmaceutical Co., Ltd. has conducted a thorough evaluation of the performance of the accounting firm Tianjian for the 2024 fiscal year, confirming its compliance with professional standards and independence [7][12][24]. - The audit committee reported that Tianjian effectively executed its quality management measures during the annual audit process, with no significant issues identified [2][11]. - The audit work plan for 2024 was comprehensive and tailored to the company's specific needs, focusing on key areas such as revenue recognition and asset impairment [3][4]. Group 2 - Tianjian has established a dedicated audit team with members possessing extensive experience in auditing listed companies, supported by experts in various fields [4]. - The company has implemented a systematic information security management framework, ensuring the confidentiality and proper handling of sensitive information during the audit process [5]. - Tianjian has accumulated over 100 million yuan in professional risk funds and liability insurance, demonstrating its capacity to manage professional risks [6]. Group 3 - The audit committee's evaluation confirmed that Tianjian adhered to independent auditing principles and provided objective and fair reflections of the company's financial status [10][12]. - The company has made changes to its accounting policies in accordance with new regulations issued by the Ministry of Finance, effective from January 1, 2024, which will not impact previously disclosed financial statements [14][22]. - The board of directors and the supervisory board have approved the changes to the accounting policies, affirming that these changes are reasonable and will not adversely affect the company's financial results [25][26].